GlassScriptPhysician profile
Jeffrey N Berger
NPI 1174526941
$2,263.05
in general payments reported to CMS, 2019-2025
19 companies · $804 in 2025
The $804 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $78.45 · 2020: $207 · 2021: $184 · 2022: $226 · 2023: $339 · 2024: $424 · 2025: $804.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,535 · Education: $32.88.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,534.62 |
| Education | $32.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $580.84 | 2020-2025 | Rinvoq, Skyrizi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $459.48 | 2021-2024 | Xifaxan, Plenvu |
| Madrigal Pharmaceuticals | $295.92 | 2024-2025 | Rezdiffra |
| Novo Nordisk INC | $274.30 | 2022-2025 | Wegovy |
| Janssen Pharmaceuticals, INC | $193.73 | 2020 | |
| Phathom Pharmaceuticals, INC. | $125.00 | 2025 | Voquezna |
| Genzyme Corporation | $66.56 | 2024-2025 | |
| Edwards Lifesciences Corporation | $35.54 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $35.45 | 2022-2024 | Entyvio |
| Celltrion USA INC. | $32.88 | 2024 | Zymfentra |
| Otsuka America Pharmaceutical, INC. | $29.17 | 2025 | Rexulti |
| Pfizer INC. | $20.67 | 2025 | |
| Celgene Corporation | $19.53 | 2023 | Zeposia |
| Ipsen Biopharmaceuticals, INC | $19.40 | 2025 | Iqirvo |
| Abbott Laboratories | $18.08 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $17.04 | 2019 | |
| Intercept Pharmaceuticals, INC. | $13.59 | 2023 | Ocaliva |
| Boston Scientific Corporation | $13.40 | 2019 | |
| Allergan, INC. | $12.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Berger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.